XAIRBEYOND AIR, INC.
Is Beyond Air struggling financially?
Yes, by its own account. Beyond Air told the SEC on 26 Jun 2026, in Form 10-K, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed Jun 2026
15/100
Critical
- Sector
- Biotech/Pharma
- Market cap
- $4.8M
- Source filing
- 10-K 26 Jun 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
1month
If the burn speeds up
Empty by Jul 2026
-
3months
If it eases off
Empty by Sep 2026
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$5.5M
÷
Cash burned over the last 12 months
$33.7M
What Beyond Air told the SEC
…our Financial Position and Capital Requirements Our independent registered public accounting firm’s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a “going concern.” Numerous factors, including the incurring of significant losses, are relevant to our financial success and any or all such factors could have a disproportionate impact on our…
BEYOND AIR, INC., Form 10-K, filed 26 Jun 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- Debt pressure is material Debt is large against the cash on hand while the business generates little to service it, which puts lenders ahead of shareholders in the queue.
- Cash burn is narrowing It is spending 56% less cash per year than it was, so the runway above is lengthening rather than shortening.
Other Biotech/Pharma companies that filed the doubt
- SNTI Senti Biosciences Holdings $12.1M
- VTGN Vistagen Therapeutics $10.8M
- VIVS VivoSim Labs $4.2M
- ATRA Atara Biotherapeutics $97.4M
- OLMA Olema Pharmaceuticals $935.3M
- NXTC NextCure $28.8M